Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab in Relapse/Refractory Lymphomas After CAR T-cells Therapy
NCT04703686Phase 2Completed
- Sponsor
- LYSARC
- Start
- Mar 2021
- Primary completion
- Jan 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab in diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), mantle cell lymphoma (MCL), Indolent Non-Hodgkin Lymphoma (INHL), non-Hodgkin lymphoma (NHL), sponsored by LYSARC. Started Mar 2021; status: completed.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)mantle cell lymphoma (MCL)Indolent Non-Hodgkin Lymphoma (INHL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04703686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04703686.